SBRT Controls Metastatic Kidney Cancer ‘For As Much as 2 Years’, Says Expert
Data from recent clinical trials indicate that stereotactic radiation can locally control metastatic kidney cancer and delay systemic therapy for close to 2 years, according to Raquibul Hannan, MD, PhD, a professor in the Department of Radiation Oncology, Urology and Immunology at the University of Texas (UT) Southwestern Medical Center in Dallas.
He went into detail about findings from a number of clinical trials, including one that was conducted at the UT Southwestern Medical Center in Dallas, that all demonstrated stereotactic radiation’s efficacy among patients with metastatic kidney cancer.
“[The trials] all showed that the 1-year and 2-year overall survival rates can be as much as 85 to 90% for these patients,” he said.
Recently, 2 prospective phase 2 trials and a prospective multi-institutional registry trial were read out, and all of them suggested that stereotactic radiation can delay the initiation of systemic therapy; it can locally control oligometastatic [renal cell carcinoma] patients for as much as 2 years. This is a paradigm that we have been practicing at UT Southwestern [Medical Center] since early 2013 and 2014. We published one of the first retrospective studies of about 47 patients where we showed that we can control these cancers for [a median of] 15 months. But recently, our own phase 2 study, MD Anderson's phase 2 study, and the multi-institutional prospective registry study all showed that the 1-year and 2-year overall survival rates can be as much as 85 to 90% for these patients, and, on average, we can delay the systemic therapy by 1 to close to 2 years.
Targeted radiation controls metastatic kidney cancer. News release. UT Southwestern Medical Center. August 1, 2019. Accessed December 2, 2022. bit.ly/3izve36